https://mindmedicinelaw.com/briefing/observing-awe-in-psilocybin-therapy-new-methods-explored-20260605-10434The Psychedelic Journalen2026-06-06T15:05:13.270510+00:00Observing Awe in Psilocybin Therapy: New Methods Exploredpsilocybin-assisted therapy, awe narration, coding system, psychedelic therapy, therapeutic mechanisms, clinical trials, advanced cancer, psychedelic research, therapeutic outcomes, scalable systemshttps://mindmedicinelaw.com/briefing/arizona-s-psilocybin-trial-progress-and-implications-20260605-10354The Psychedelic Journalen2026-06-05T22:04:21.914941+00:00Arizona's Psilocybin Trial: Progress and Implicationspsilocybin trial, Arizona, psychedelic research, mental health, clinical trials, regulatory policy, serotonin receptors, Schedule I substance, treatment-resistant conditionshttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-under-tsca-impacts-on-psychedelic-research-20260605-10064The Psychedelic Journalen2026-06-05T22:04:14.238920+00:00EPA's Proposed SNURs Under TSCA: Impacts on Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, import, notification, policyhttps://mindmedicinelaw.com/briefing/post-trial-psilocybin-access-legal-reflections-in-the-uk-20260605-10197The Psychedelic Journalen2026-06-05T15:05:11.837310+00:00Post-Trial Psilocybin Access: Legal Reflections in the UKpsilocybin, post-trial access, UK legal case, psychedelic research, clinical trials, Schedule 1 drugs, patient access, regulatory frameworks, mental health treatment, legal complexitieshttps://mindmedicinelaw.com/briefing/kainic-acid-pig-model-advances-epilepsy-neuromodulation-20260604-10445The Psychedelic Journalen2026-06-06T15:04:47.101134+00:00Kainic Acid Pig Model Advances Epilepsy Neuromodulationkainic acid, porcine model, mesial temporal lobe epilepsy, neuromodulation, implantable devices, translational research, epilepsy therapies, clinical trials, neuroscience, large-animal modelshttps://mindmedicinelaw.com/briefing/psychedelics-for-chronic-pain-review-highlights-challenges-20260604-10400The Psychedelic Journalen2026-06-06T15:04:38.305695+00:00Psychedelics for Chronic Pain: Review Highlights Challengespsychedelics, chronic pain, clinical trials, neuroplasticity, safety considerations, regulatory challenges, psilocybin, LSD, pain management, future researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-social-anxiety-trial-insights-20260604-10421The Psychedelic Journalen2026-06-06T15:04:29.523178+00:00MDMA-Assisted Therapy for Social Anxiety: Trial InsightsMDMA, MDMA-Assisted Therapy, social anxiety disorder, clinical trial, psychedelics, mental health treatment, therapy, neuroscience, psychiatry, regulatory implicationshttps://mindmedicinelaw.com/briefing/eeg-study-explores-awe-in-affective-disorders-20260604-10118The Psychedelic Journalen2026-06-05T22:04:40.390349+00:00EEG Study Explores Awe in Affective Disordersaffective disorders, awe experience, EEG study, virtual reality, emotional processing, neural activity, theta oscillations, therapeutic interventions, mental health treatment, neurobiological researchhttps://mindmedicinelaw.com/briefing/ketamine-induced-neuronal-death-adult-rats-study-insights-20260604-10129The Psychedelic Journalen2026-06-05T22:04:33.097835+00:00Ketamine-Induced Neuronal Death: Adult Rats Study Insightsketamine neurotoxicity, adult female rats, neuronal necrosis, norketamine metabolite, depression treatment, safety profile, clinical research, age-specific risks, sex-specific vulnerability, psychedelic researchhttps://mindmedicinelaw.com/briefing/ai-chatbots-and-substance-induced-psychosis-clinical-concerns-20260604-10083The Psychedelic Journalen2026-06-05T15:05:29.597502+00:00AI Chatbots and Substance-Induced Psychosis: Clinical ConcernsAI chatbots, substance-induced psychosis, mental health, clinical implications, ethical concerns, harm minimizationhttps://mindmedicinelaw.com/briefing/mdma-booster-dose-study-implications-for-clinical-trials-20260604-10103The Psychedelic Journalen2026-06-05T15:05:22.021857+00:00MDMA Booster Dose Study: Implications for Clinical TrialsMDMA booster dose, psychedelic therapy, PTSD treatment, clinical trials, subjective effects, adverse effects, dosing protocols, psychiatric disorders, MDMA-assisted therapy, neuroscience researchhttps://mindmedicinelaw.com/briefing/connecticut-expands-psychedelics-program-ahead-of-fda-approval-20260604-10195The Psychedelic Journalen2026-06-05T15:05:00.074307+00:00Connecticut Expands Psychedelics Program Ahead of FDA Approvalconnecticut psychedelics program, FDA approval, psychedelic therapy, state-level policy, clinical trials, psychedelics legal landscapehttps://mindmedicinelaw.com/briefing/ketamine-therapy-gains-traction-in-las-vegas-clinic-20260604-10037The Psychedelic Journalen2026-06-04T22:04:17.711278+00:00Ketamine Therapy Gains Traction in Las Vegas Clinicketamine therapy, mental health, psychedelic treatments, Las Vegas clinic, alternative therapies, clinical research, policy implications, treatment risks, healthcare integration, patient outcomeshttps://mindmedicinelaw.com/briefing/ketamine-oxytocin-nasal-spray-a-new-frontier-in-la-20260604-10036The Psychedelic Journalen2026-06-04T22:04:10.874021+00:00Ketamine-Oxytocin Nasal Spray: A New Frontier in LAketamine, oxytocin, nasal spray, treatment-resistant depression, PTSD, compounded formulations, mental health treatment, clinical trials, regulatory scrutiny, psychedelic therapieshttps://mindmedicinelaw.com/briefing/ibogaine-s-role-in-addiction-treatment-a-literature-review-20260603-10119The Psychedelic Journalen2026-06-06T15:04:56.117360+00:00Ibogaine's Role in Addiction Treatment: A Literature Reviewibogaine, addiction treatment, substance use disorders, clinical trials, cardiac risks, regulatory criteriahttps://mindmedicinelaw.com/briefing/n100-and-fronto-limbic-metabolism-in-mdd-new-insights-20260603-10135The Psychedelic Journalen2026-06-05T22:04:47.386129+00:00N100 and Fronto-Limbic Metabolism in MDD: New InsightsN100 potential, major depressive disorder, GABAergic systems, cerebral glucose metabolism, transcranial magnetic stimulation, compensatory mechanism, fronto-limbic metabolism, Hamilton Depression Rating Scale, targeted therapies, neurophysiological mechanismhttps://mindmedicinelaw.com/briefing/hnk-s-antidepressant-mechanism-opioid-receptor-heterodimerization-20260603-10133The Psychedelic Journalen2026-06-05T15:05:50.180478+00:00HNK's Antidepressant Mechanism: Opioid Receptor HeterodimerizationHNK, opioid receptor heterodimerization, antidepressant mechanism, ketamine metabolite, astrocytic receptors, rapid-acting antidepressants, mental health treatment, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/shared-molecular-pathways-in-mood-disorders-new-insights-20260603-10134The Psychedelic Journalen2026-06-05T15:05:39.767004+00:00Shared Molecular Pathways in Mood Disorders: New Insightsmood disorders, human habenula, transcriptomic profiling, major depressive disorder, bipolar disorder, sex-informed research, neurobiology, therapeutic strategies, gene expression, psychiatric researchhttps://mindmedicinelaw.com/briefing/ketamine-s-potential-in-treating-chemobrain-a-preclinical-study-20260601-9814The Psychedelic Journalen2026-06-04T22:04:24.131366+00:00Ketamine's Potential in Treating Chemobrain: A Preclinical Studyketamine, chemobrain, depression, neuroinflammation, cancer treatment, preclinical study, signaling pathways, BDNF/TrkB, GLT-1, SERThttps://mindmedicinelaw.com/briefing/brazil-s-psychedelic-psychiatric-use-a-scoping-review-20260530-10442The Psychedelic Journalen2026-06-06T15:05:05.529026+00:00Brazil's Psychedelic Psychiatric Use: A Scoping Reviewbrazil, ayahuasca, psychedelic research, psychiatric disorders, dmt, ibogaine, substance use disorders, clinical trials, mental health, cultural integrationhttps://mindmedicinelaw.com/briefing/ketamine-s-dual-effects-neurotoxicity-and-neuroprotection-20260527-10175The Psychedelic Journalen2026-06-05T22:04:04.870135+00:00Ketamine's Dual Effects: Neurotoxicity and Neuroprotectionketamine, esketamine, neurotoxicity, neuroprotection, clinical guidelines, brain health, therapeutic use, systematic review, neuroscience, public health